Skip to main content
. 2023 Oct 25;16(11):1517. doi: 10.3390/ph16111517

Table 1.

Lawsuits filed (resolved) against biosimilar candidates (Effective 21 September 2023) [39].

Drug Number of Lawsuits (#Resolved)
Aflibercept 1
Denosumab 1
Natalizumab 1
Tocilizumab 1
Adalimumab 5 (5)
Bevacizumab 4 (4)
Epoetin alfa 2 (2)
Etanercept 2 (2)
Filgrastim 5 (5)
Infliximab 2 (2)
Pegfilgrastim 6 (6)
Rituximab 2 (2)
Trastuzumab 5 (5)
Ustekinumab 1 (1)